Chronic hepatitis B
Conditions
Interventions
Intervention group:Pegylated Interferon Alpha-2b
Sponsors
The First People's Hospital of Yunnan Province
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-60 years old; 2. Comply with the clinical diagnostic criteria in the "Guidelines for the Prevention and Treatment of Chronic Hepatitis B" (2019 Edition) regarding the immune tolerance period; 3. Have not received antiviral treatment within six months before being selected; 4. For patients of childbearing age, agree to choose appropriate contraceptive measures (including at least one barrier contraceptive method) throughout the trial period; 5. Volunteer to join this study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those who have used hepatoprotective drugs within 1 month before being selected; 2. Serum anti-HIV positive; 3. Liver diseases caused by other causes, such as hepatitis C, severe fatty liver, autoimmune liver disease, drug-induced hepatitis, etc.; 4. Patients who have progressed to liver cirrhosis or liver cancer; 5. Accompanied by serious or uncontrollable underlying diseases; 6. Pregnant and lactating women; 7. Suspected or do have a history of alcohol or drug abuse; 8. Those who are participating in other hepatitis drug trials within 3 months or currently; 9. Subjects who are unsuitable to participate in the research based on the researcher's judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seroconversion rates of HBeAg; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete virological response rate; | — |
Countries
China
Contacts
Public ContactGeng Jiawei
The First People's Hospital of Yunnan Province
Outcome results
None listed